What The Health with Emily Casey
About Michael Winlo
Dr Michael Winlo is Founder and Chief Scientific Officer of Emyria, the ASX-listed company behind the Empax network of clinics that help evaluate psychedelic-assisted therapies for post-traumatic stress disorder and treatment-resistant depression. He also oversees the company's research and drug discovery programs.
A medical graduate of the University of Western Australia with an MBA from Stanford, he holds patents in health data analysis. He spent four years growing the health practice of Palantir Technologies in Silicon Valley and New York, then from 2016 led Linear Clinical Research, the clinical trials arm of Perth's Harry Perkins Institute of Medical Research, before founding Emyria in 2019 (initially called Emerald Clinics). On What The Health with Emily Casey, he explained how psychedelic medicine is moving from counterculture to clinical treatment.
- Talks about
- Deep Tech & Science, Founder Journey, Health & Biotech
In conversation.
1 episode
What The Health with Emily Casey Go straight to the good bits.
Key moments from The Psychedelic Resurgence: From Counterculture to Clinical Breakthrough with Dr Michael Winlo.
- 0:00Psychedelics return to healthcare
- 0:57What Emyria and the Empax clinics do
- 2:08From medicine to Palantir and back to Perth
- 8:32Why mental health care is falling behind
- 12:37What psychedelics actually are
- 13:55How MDMA-assisted therapy works
- 17:44Psilocybin and the default mode network
- 21:05A century of history: from Merck to the war on drugs
- 24:18The revival: MAPS, new trials and Australia's rescheduling
- 27:17Why psychiatry innovates slowly
The path so far.
- Now
Chief Scientific Officer · Emyria
- Until 2019 · Scale-up
CEO · Linear Clinical Research
- Earlier · Scale-up
Health Lead · Palantir Technologies
- Earlier · Startup
Founding CEO · Cerulean Medical
Sources: rocketreach.co
Emyria on Day One
Emyria (ASX:EMD) is a Perth-based, ASX-listed biotech developing treatments for mental health and neurological conditions, including psychedelic-assisted therapies…
1 person · 1 episode
Across the network.
In the room with
Spot something wrong? Suggest a correctionUpdated 10 November 2026
Be part of
the conversation.
Put your brand alongside the voices founders, investors and operators come to hear.
Explore sponsorshipWant a show of your own?
W2D1 Media — the team behind the Day One Network, which helped build Blackbird Ventures' Wild Hearts — builds and produces podcasts for funds, founders and operators. If you want a show built around your brand, let's talk.
